Literature DB >> 29683958

Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study.

Motohiro Matsui1, Yuya Saito1, Shoko Yamaoka1, Yuichi Yokokawa1, Yoshihiko Morikawa2, Atsushi Makimoto1, Yuki Yuza1.   

Abstract

In total, 158 chemotherapy courses containing cisplatin for 37 pediatric cases of newly diagnosed cancer were divided into 2 groups depending on whether magnesium (Mg) supplementation was administered (Mg+: 92 courses) or not (Mg-: 66 courses). Renal impairment was defined as grade 2 or higher creatinine elevation (CE) after each chemotherapy course. The incidence of CE in the Mg+ was significantly lower than in the Mg- (9.8% vs. 22.7%; P=0.025). Multivariate analysis revealed that Mg supplementation significantly reduced the incidence of CE (odds ratio, 0.36; confidence interval, 0.13-0.99). In pediatric patients, Mg supplementation during cisplatin-containing chemotherapy was associated with less cisplatin-induced nephrotoxicity to prevent cisplatin-induced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29683958     DOI: 10.1097/MPH.0000000000001159

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

Review 1.  Optimizing Rhabdomyosarcoma Treatment in Adolescents and Young Adults.

Authors:  Atsushi Makimoto
Journal:  Cancers (Basel)       Date:  2022-05-02       Impact factor: 6.575

2.  Long-Term Tubular Dysfunction in Childhood Cancer Survivors; DCCSS-LATER 2 Renal Study.

Authors:  Esmee C M Kooijmans; Helena J H van der Pal; Saskia M F Pluijm; Margriet van der Heiden-van der Loo; Leontien C M Kremer; Dorine Bresters; Eline van Dulmen-den Broeder; Marry M van den Heuvel-Eibrink; Jacqueline J Loonen; Marloes Louwerens; Sebastian J C Neggers; Cécile Ronckers; Wim J E Tissing; Andrica C H de Vries; Gertjan J L Kaspers; Arend Bökenkamp; Margreet A Veening
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

3.  Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity.

Authors:  Alfredo G Casanova; María Teresa Hernández-Sánchez; Francisco J López-Hernández; Carlos Martínez-Salgado; Marta Prieto; Laura Vicente-Vicente; Ana Isabel Morales
Journal:  Eur J Clin Pharmacol       Date:  2019-11-01       Impact factor: 2.953

4.  Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin.

Authors:  Mary Elizabeth Money; Aghiles Hamroun; Yan Shu; Carolyn Matthews; Sara Ahmed Eltayeb; Giuliano Ciarimboli; Christine Noel Metz
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

5.  Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: A protocol for a randomized phase 2 trial.

Authors:  Atsushi Makimoto; Motohiro Matsui; Motoaki Chin; Katsuyoshi Koh; Masako Tomotsune; Tetsuji Kaneko; Yoshihiko Morikawa; Yuki Yuza
Journal:  Contemp Clin Trials Commun       Date:  2019-08-22

6.  Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway.

Authors:  Xiaozhong Liao; Ying Gao; Jiahui Liu; Lanting Tao; Jun Xie; Yueyu Gu; Taoli Liu; Dongmei Wang; Dan Xie; Suilin Mo
Journal:  Front Oncol       Date:  2020-09-10       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.